Current standard practice for intravenous monitoring relies heavily on tactile and visual observation, a method frequently unable to catch fluid leakage until tissue damage is already underway. The SmartTouch+ sensor expands the company's existing platform to include lipid-based solutions, performing over 18,000 checks per hour to identify when fluid escapes the vein. This capability is intended to protect vulnerable populations, such as infants in neonatal units or surgical patients whose IV sites are obscured by drapes.

Erin Wendell, president of ivWatch, noted that clinical demand for this technology stems from the high risk associated with peripheral infusions of opaque fluids, which often lead to significant liability and patient harm. While the device is currently under FDA review, its design is intended for integration into existing clinical workflows across diverse healthcare settings. The company, which holds nearly 70 patents, continues to build on its intellectual property portfolio to address the persistent issue of peripheral IV failure, a complication that affects up to 50% of all hospital IV procedures.